Michael B. Atkins
0000-0003-3901-9924
Publication & Citation Trends
Publications
0 total
Abstract A003: Hsp70 gene expression is enriched in lymphocytes in renal cell carcinoma patients that respond to immune checkpoint inhibitors
Cited by 0
Semantic Scholar
Effects of Vemurafenib ± Cobimetinib on Intratumoral and Host Immunity in Patients With BRAFV600 Mutant Melanoma: Implications for Combination With Immunotherapy
Cited by 0
Semantic Scholar
Abstract A020: Tumor-infiltrating lymphocytes and peritumoral tertiary lymphoid structures as biomarkers of response to first-line nivolumab plus ipilimumab in patients with metastatic clear cell renal cell carcinoma enrolled in the COSMIC 313 trial
Cited by 0
Semantic Scholar
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of renal cell carcinoma, version 3.0
Cited by 0
Semantic Scholar
Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: final analysis of efficacy and safety from the phase III CheckMate 214 trial.
Cited by 2
Semantic Scholar
Abstract 3999: Pan-cancer prediction of response to immune checkpoint blockade from histopathology
Cited by 0
Semantic Scholar
Ascending dose escalation of belzutifan plus palbociclib for previously treated advanced clear cell renal cell carcinoma (ccRCC): Phase 1/2 LITESPARK-024 study part 1.
Cited by 0
Semantic Scholar
Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinoma
Cited by 0
Semantic Scholar
Research Topics
Cancer Immunotherapy and Biomarkers
(437)
Renal cell carcinoma treatment
(407)
CAR-T cell therapy research
(227)
Cancer Genomics and Diagnostics
(151)
Renal and related cancers
(143)
Affiliations
Université Claude Bernard Lyon 1
BHP (Australia)
Broad Institute
University of Southern California
Louisiana State University